Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26036118 | 0.96 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL21509219 | 0.88 | CA1 (0.48) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22815569 | 0.83 | PARP15 (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL14480739 | 0.83 | PARP15 (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL387330 | 0.82 | PARP15 (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19387935 | 0.81 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL17072248 | 0.81 | MEN1 (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16178844 | 0.80 | CA1 (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16622998 | 0.80 | TDP1 (0.57) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL4664263 | 0.79 | CXCR1 (0.46) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | DIC CORPORATION (JP) | 2023-08-29 | — | — | US | disclosed |
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | DIC CORPORATION (JP) | 2023-08-29 | — | — | US | disclosed |
| US-20200399539-A1 | POLYMERIZABLE COMPOUND AS WELL AS LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE EACH INCLUDING POLYMERIZABLE COMPOUND | DIC CORPORATION (JP) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | OCIAD2, PKN2, SKP1 | LPL 1920/4885LIPG 3805/4885CA1 1223/4885 |
| US-20200399539-A1 | POLYMERIZABLE COMPOUND AS WELL AS LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE EACH INCLUDING POLYMERIZABLE COMPOUND | OCIAD2, PKN2, SKP1 | LPL 1920/4885LIPG 3805/4885CA1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.